Allena Pharmaceuticals
Geoffrey Swire joined Allena in 2018 and currently serves as the vice president of business development and strategy. Mr. Swire has 20 years of leadership experience in business, product, and commercial development for life sciences companies.
Mr. Swire previously worked at Radius Health, where he served as head of business development and alliance management, and earlier as program leader for the global Phase 3 osteoporosis development program (Tymlos, FDA approved in 2017). Prior to that, Mr. Swire spent seven years at Genzyme in various leadership positions in the Transplant and Oncology business units, including head of program and portfolio management, as well as vice president of global commercial operations. While at Genzyme, Mr. Swire played a central role in the acquisition, development, regulatory approvals, and global commercial launch of Mozobil for patients undergoing stem cell transplants. Mr. Swire started his career in strategy and product development consulting at Integral, Inc., and Accenture’s Health & Life Sciences practice.
Mr. Swire holds a B.A. in French and History from Dartmouth College and a Masters in Public Policy from Harvard University.
This person is not in any offices
Allena Pharmaceuticals
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.